Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 10
2013 5
2014 11
2015 18
2016 16
2017 18
2018 35
2019 24
2020 29
2021 30
2022 32
2023 35
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Defining Primary Refractory Large B-cell Lymphoma.
Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks TW, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS. Bock AM, et al. Among authors: nastoupil lj. Blood Adv. 2024 Apr 26:bloodadvances.2024012760. doi: 10.1182/bloodadvances.2024012760. Online ahead of print. Blood Adv. 2024. PMID: 38669353
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: nastoupil lj. J Clin Oncol. 2024 Mar 28:JCO2302329. doi: 10.1200/JCO.23.02329. Online ahead of print. J Clin Oncol. 2024. PMID: 38547425
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M. Crombie JL, et al. Among authors: nastoupil l. Blood. 2024 Apr 18;143(16):1565-1575. doi: 10.1182/blood.2023022432. Blood. 2024. PMID: 38252906
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Lionel AC, et al. Among authors: nastoupil lj. Leuk Lymphoma. 2024 May;65(5):669-673. doi: 10.1080/10428194.2024.2304622. Epub 2024 Jan 22. Leuk Lymphoma. 2024. PMID: 38248629 No abstract available.
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Marin D, et al. Among authors: nastoupil lj. Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18. Nat Med. 2024. PMID: 38238616 Free PMC article. Clinical Trial.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. Cerhan JR, et al. Among authors: nastoupil lj. Am J Hematol. 2024 Mar;99(3):408-421. doi: 10.1002/ajh.27202. Epub 2024 Jan 13. Am J Hematol. 2024. PMID: 38217361
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Dreyling M, et al. Among authors: nastoupil lj. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. Blood. 2024. PMID: 38194692 Free PMC article. Clinical Trial.
240 results